{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T06:51:12Z","timestamp":1777099872492,"version":"3.51.4"},"reference-count":34,"publisher":"BMJ","issue":"12","funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","award":["SMA-PC BI"],"award-info":[{"award-number":["SMA-PC BI"]}],"id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","award":["SMA-PC BA"],"award-info":[{"award-number":["SMA-PC BA"]}],"id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Company","doi-asserted-by":"publisher","award":["SMA-PC DS"],"award-info":[{"award-number":["SMA-PC DS"]}],"id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848015004"],"award-info":[{"award-number":["848015004"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","award":["SMA-PC BMS\/Pfizer"],"award-info":[{"award-number":["SMA-PC BMS\/Pfizer"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2019,11,25]]},"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Clinical guidelines recommend non-vitamin K antagonist oral anticoagulants (NOACs) over vitamin K antagonists (VKAs) for stroke prevention in most patients with atrial fibrillation (AF). Frail elderly were under-represented in the landmark NOAC-trials, leaving a knowledge gap on the optimal anticoagulant management (VKA or NOAC) in this increasing population. The aim of the Frail-AF (FRAIL-AF) study is to assess whether switching from international normalised ratio (INR)-guided VKA-management to a NOAC-based treatment strategy compared with continuing VKA-management is safe in frail elderly patients with AF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>\n                      The FRAIL-AF study is a pragmatic, multicentre, open-label, randomised controlled clinical trial. Frail elderly (age \u226575 years plus a Groningen Frailty Indicator score \u22653) who receive VKA-treatment for AF in the absence of a mechanical heart valve or severe mitral valve stenosis will be randomised to switch to a NOAC-based treatment strategy or to continue INR-guided VKA-management. Patients with severe renal impairment (estimated glomerular filtration rate &lt;30\u2009mL\/min\/1.73\u2009m\n                      <jats:sup>2<\/jats:sup>\n                      ) will be excluded from randomisation. Based on existing trial evidence in non-frail patients, we will aim to explore whether NOAC-treatment is superior to VKA-therapy in reducing major or clinically relevant non-major bleeding events. Secondary outcomes include minor bleeding, the composite of ischaemic and haemorrhagic stroke, health-related quality of life and cost-effectiveness. The follow-up period for all subjects is 12 months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>The protocol was approved by the Medical Research Ethics Committee of the University Medical Center Utrecht, the Netherlands and by the Central Committee on Research Involving Human Subjects, the Netherlands. All patients are asked written informed consent. Results are expected in 2022 and will be disseminated through peer-reviewed journals as well as presentations at national and international conferences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>EudraCT: 2017-000393-11; The Netherlands Trial Registry: 6721 (FRAIL-AF study).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-032488","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T04:25:23Z","timestamp":1577679923000},"page":"e032488","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0926-9749","authenticated-orcid":false,"given":"Linda P T","family":"Joosten","sequence":"first","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4319-3503","authenticated-orcid":false,"given":"Sander","family":"van Doorn","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arno W","family":"Hoes","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melchior C","family":"Nierman","sequence":"additional","affiliation":[{"name":"Department of Thrombosis and Anticoagulation, Atalmedial Medical Diagnostics Centers, Amsterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nynke M","family":"Wiersma","sequence":"additional","affiliation":[{"name":"Department of Thrombosis and Anticoagulation, Diagnostic Center Saltro, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiberdina L","family":"Koek","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin E W","family":"Hemels","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands"},{"name":"Department of Cardiology, Radboud University Medical Center, Radboud University, Nijmegen, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Menno V","family":"Huisman","sequence":"additional","affiliation":[{"name":"Department of Thrombosis and Hemostasis, Leiden University Medical Center, Leiden University, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kit C","family":"Roes","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rutger M","family":"van den Bor","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim F","family":"Buding","sequence":"additional","affiliation":[{"name":"Member of the Dutch Organisation for patients using anticoagulant medication, CTD Nederland, Leiden, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans H","family":"Rutten","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert-Jan","family":"Geersing","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,12,29]]},"reference":[{"key":"2025121602065913000_9.12.e032488.1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi825"},{"key":"2025121602065913000_9.12.e032488.2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.161.20.2458"},{"key":"2025121602065913000_9.12.e032488.3","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007"},{"key":"2025121602065913000_9.12.e032488.4","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.13.1527"},{"key":"2025121602065913000_9.12.e032488.5","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.907140"},{"key":"2025121602065913000_9.12.e032488.6","first-page":"567","article-title":"Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin","volume":"6","author":"Zalesak","year":"2013","journal-title":"Circulation"},{"key":"2025121602065913000_9.12.e032488.7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med Overseas Ed"},{"key":"2025121602065913000_9.12.e032488.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638"},{"key":"2025121602065913000_9.12.e032488.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039"},{"key":"2025121602065913000_9.12.e032488.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907"},{"key":"2025121602065913000_9.12.e032488.11","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013267"},{"key":"2025121602065913000_9.12.e032488.12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.115.002369"},{"key":"2025121602065913000_9.12.e032488.13","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezw313"},{"key":"2025121602065913000_9.12.e032488.14","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12087"},{"key":"2025121602065913000_9.12.e032488.15","doi-asserted-by":"publisher","DOI":"10.1159\/000352062000352062"},{"key":"2025121602065913000_9.12.e032488.16","doi-asserted-by":"crossref","unstructured":"Hellfritzsch M , Adelborg K , Damkier P , et al . Effectiveness and safety of direct oral anticoagulants in atrial fibrillation patients switched from vitamin K antagonists: a systematic review and meta\u2010analysis. Basic Clin Pharmacol Toxicol 2019;128.doi:10.1111\/bcpt.13283","DOI":"10.1111\/bcpt.13283"},{"key":"2025121602065913000_9.12.e032488.17","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-3-201302050-00583"},{"key":"2025121602065913000_9.12.e032488.18","first-page":"236","article-title":"Measuring frailty: developing and testing the GFI (Groningen frailty indicator)","volume":"41","author":"Steverink","year":"2001","journal-title":"Gerontologist"},{"key":"2025121602065913000_9.12.e032488.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2012.08.001"},{"key":"2025121602065913000_9.12.e032488.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61233-1"},{"key":"2025121602065913000_9.12.e032488.21","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/jamainternmed.2016.3057","article-title":"Risk of bleeding and thrombosis in patients 70 years or older using vitamin K antagonists","volume":"176","author":"Kooistra","year":"2016","journal-title":"JAMA Intern Med"},{"key":"2025121602065913000_9.12.e032488.22","unstructured":"Boehringer Ingelheim Pharma GmbH & Co . KG. Samenvatting van de productkenmerken van dabigatran. Available: http:\/\/www.ema.europa.eu\/docs\/nl_NL\/document_library\/EPAR_-_Product_Information\/human\/000262\/WC500027361.pdf [Accessed 1 Aug 2018]."},{"key":"2025121602065913000_9.12.e032488.23","unstructured":"Bayer Pharma AG and Bayer HealthCare Manufacturing S.r.l. Samenvatting van de productkernmerken van rivaroxaban. Available: http:\/\/www.ema.europa.eu\/docs\/nl_NL\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf [Accessed 1 Aug 2018]."},{"key":"2025121602065913000_9.12.e032488.24","unstructured":"Bristol-Myers Squibb S.r.l. and Phizer Manufacturing Deutschland GmbH. Samenvatting van de productkenmerken van apixaban. Available: http:\/\/www.ema.europa.eu\/docs\/nl_NL\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf [Accessed 1 Aug 2018]."},{"key":"2025121602065913000_9.12.e032488.25","unstructured":"Daiichi Sankyo Europa GmbH. Samenvatting van de productkenmerken van edoxaban. Available: http:\/\/www.ema.europa.eu\/docs\/nl_NL\/document_library\/EPAR_-_Product_Information\/human\/000262\/WC500027361.pdf [Accessed 1 Aug 2018]."},{"key":"2025121602065913000_9.12.e032488.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"2025121602065913000_9.12.e032488.27","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13140"},{"key":"2025121602065913000_9.12.e032488.28","unstructured":"Hakkaart-van Roijen L , van der Linden N , Bouwmans C , et al . Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg, 2015: 1\u201324."},{"key":"2025121602065913000_9.12.e032488.29","unstructured":"World Medical Association . WMA Declaration of Helsinki -Ethical principles for medical research involving human subjects, 2013."},{"key":"2025121602065913000_9.12.e032488.30","unstructured":"Wet medisch-wetenschappelijk onderzoek met mensen, 1998. Available: https:\/\/wetten.overheid.nl\/BWBR0009408\/2018-08-01 [Accessed 1 Aug 2018]."},{"key":"2025121602065913000_9.12.e032488.31","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1111\/bjh.15856","article-title":"Choosing between continuing vitamin K antagonists (VKA) or switching to a direct oral anticoagulant in currently well-controlled patients on VKA for atrial fibrillation: a randomised controlled trial (GAInN)","volume":"186","author":"van Miert","year":"2019","journal-title":"Br J Haematol"},{"key":"2025121602065913000_9.12.e032488.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2009.11.025"},{"key":"2025121602065913000_9.12.e032488.33","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/MJT.0b013e3182373591","article-title":"Study of warfarin patients investigating attitudes toward therapy change (SWITCH survey)","volume":"19","author":"Attaya","year":"2012","journal-title":"Am J Ther"},{"key":"2025121602065913000_9.12.e032488.34","first-page":"368","article-title":"When do patients prefer a direct oral anticoagulant over a vitamin K antagonist?","volume":"73","author":"Boom","year":"2015","journal-title":"Neth J Med"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-032488","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T10:07:07Z","timestamp":1765879627000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-032488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,12,29]]},"published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1136\/bmjopen-2019-032488"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-032488","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}